Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024PRNewsWire • 07/29/24
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationPRNewsWire • 07/02/24
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePRNewsWire • 06/13/24
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer TestingPRNewsWire • 06/12/24
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial ResultsPRNewsWire • 05/13/24
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA RecallPRNewsWire • 05/09/24
Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of DirectorsPRNewsWire • 05/07/24
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer TestingPRNewsWire • 05/02/24
PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research InstitutePRNewsWire • 04/30/24
Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness MonthPRNewsWire • 04/29/24
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/24
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 03/26/24
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationPRNewsWire • 03/21/24
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpXPRNewsWire • 03/21/24
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 ConferencePRNewsWire • 03/20/24